DOI QR코드

DOI QR Code

Comparison of Two Apheresis Systems of COBE and Optia for Autologous Peripheral Blood Stem Cell Collection

  • Lee, Se-Na (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Sohn, Ji Yeon (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Kong, Jung Hee (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center) ;
  • Eom, Hyeon Seok (Center for Hematologic Malignancy, National Cancer Center) ;
  • Lee, Hyewon (Center for Hematologic Malignancy, National Cancer Center) ;
  • Kong, Sun-Young (Department of Laboratory Medicine, Center for Diagnostic Oncology, National Cancer Center)
  • Received : 2016.08.08
  • Accepted : 2017.03.16
  • Published : 2017.07.01

Abstract

Peripheral blood stem cell (PBSC) transplantation following myeloablative therapy is a mainstay of treatment for various types of malignancies. This study aimed to evaluate the differences between the Optia MNC and COBE Spectra MNC systems (Terumo BCT, Japan) according to apheresis procedures and the parameters of apheresis, products, and collection. The clinical data of 74 patients who underwent autologous PBSC collection from July 2012 to July 2015 were reviewed retrospectively. The patients comprised 48 (65%) men and 26 (35%) women with a median age of 56 yr (range, 23-66 yr). Of 216 procedures, 111 (51%) and 105 (49%) were processed by using COBE and Optia MNC, respectively. PBSC collection rates, throughput, numbers of stem cells retrieved, collection efficacy, and platelet loss were compared. There were no significant differences in the median CD34+ cell counts of collected products ($0.61{\times}10^8$ vs $0.94{\times}10^8$), CD34 collection efficiency (43.5% vs 42.1%), and loss of platelets (40.1% vs 44.7%). The Spectra Optia MNC apheresis system was comparable to the COBE Spectra system in collecting autologous CD34+ hematopoietic stem cells and retention of platelets.

Acknowledgement

Supported by : National Cancer Center, National Research Foundation of Korea (NRF)

References

  1. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32. https://doi.org/10.1182/blood-2003-04-1045
  2. Li DQ, Hou YF, Wu J, Chen Y, Lu JS, Di GH, et al. Gene expression profile analysis of an isogenic tumour metastasis model reveals a functional role for oncogene AF1Q in breast cancer metastasis. Eur J Cancer 2006; 42:3274-86. https://doi.org/10.1016/j.ejca.2006.07.008
  3. Ikeda K, Ohto H, Nemoto K, Yamamoto G, Kato K, Ogata T, et al. Collection of MNCs and progenitor cells by two separators for PBPC transplantation: a randomized crossover trial. Transfusion 2003;43:814-9. https://doi.org/10.1046/j.1537-2995.2003.00422.x
  4. Heuft HG, Dubiel M, Rick O, Kingreen D, Serke S, Schwella N. Inverse relationship between patient peripheral blood CD34+ cell counts and collection efficiency for CD34+ cells in two automated leukapheresis systems. Transfusion 2001;41:1008-13. https://doi.org/10.1046/j.1537-2995.2001.41081008.x
  5. Karafin MS, Graminske S, Erickson P, Walters MC, Scott EP, Carter S, et al. Evaluation of the Spectra Optia apheresis system for mononuclear cell (MNC) collection in G-CSF mobilized and nonmobilized healthy donors: results of a multicenter study. J Clin Apher 2014;29:273-80. https://doi.org/10.1002/jca.21319
  6. Brauninger S, Bialleck H, Thorausch K, Felt T, Seifried E, Bonig H. Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems. Transfusion 2012;52:1137-45. https://doi.org/10.1111/j.1537-2995.2011.03414.x
  7. TerumoBCT, Spectra $Optia^{(R)}$ Apheresis System. http://www.terumobct.com/location/north-america/products-and-services/Pages/spectra-optia-apheresis-system.aspx. (Last accessed on Dec 1, 2015).
  8. Brauninger S, Bialleck H, Thorausch K, Seifried E, Bonig H. Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5.0, a novel, automatic interface-controlled apheresis system: results from the first feasibility trial. Vox Sang 2011;101:237-46. https://doi.org/10.1111/j.1423-0410.2011.01484.x
  9. TerumoBCT, $COBE^{(R)}$ Spectra Apheresis Syetem. https://www.terumobct. com/location/north-america/products-and-services/Pages/COBE-spectra-apheresis-system.aspx. (Last accessed on Dec 1, 2015).
  10. Suh C, Kim S, Kim SH, Kim EK, Lee JL, Park KU, et al. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004;44:1762-8. https://doi.org/10.1111/j.0041-1132.2004.04166.x
  11. Kim MK, Kim S, Jang G, Lee SS, Sym SJ, Lee DH, et al. A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm3 versus 50/mm3 as a surrogate marker to initiate efficient autologous blood stem cell collection. J Clin Apher 2007;22:277-82. https://doi.org/10.1002/jca.20148
  12. Lefrere F, Zohar S, Beaudier S, Audat F, Ribeil JA, Ghez D, et al. Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. Transfusion 2007;47:1851-7. https://doi.org/10.1111/j.1537-2995.2007.01407.x
  13. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70. https://doi.org/10.1002/(SICI)1097-0320(19980415)34:2<61::AID-CYTO1>3.0.CO;2-F
  14. Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S, Mosiman VL. Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy 2009;11:595-605. https://doi.org/10.1080/14653240902923161
  15. Ford CD, Lehman C, Strupp A, Kelley L. Comparison of CD34+ cell collection efficiency on the COBE Spectra and Fenwal CS-3000 Plus. J Clin Apher 2002;17:17-20. https://doi.org/10.1002/jca.10011
  16. Reinhardt P, Brauninger S, Bialleck H, Thorausch K, Smith R, Schrezenmeier H, et al. Automatic interface-controlled apheresis collection of stem/ progenitor cells: results from an autologous donor validation trial of a novel stem cell apheresis device. Transfusion 2011;51:1321-30. https://doi.org/10.1111/j.1537-2995.2010.02992.x
  17. Long G, Waller EK, Gregurek S, Tricot G, Marschner S, Bill J. Evaluation of the spectra $Optia^{(R)}$ mononuclear cell collection procedure in multiple myeloma patients. J Clin Apher 2015;30:1-7. https://doi.org/10.1002/jca.21341
  18. Flommersfeld S, Bakchoul T, Bein G, Wachtel A, Loechelt C, Sachs UJ. A single center comparison between three different apheresis systems for autologous and allogeneic stem cell collections. Transfus Apher Sci 2013;49:428-33. https://doi.org/10.1016/j.transci.2013.06.002
  19. Lee JS, Cho D, Shin MG, Ryang DW, Lee JJ, Kim HJ, et al. Comparison of Amicus and CS-3000 Plus for the collection of peripheral blood stem cells. Korean J Blood Transfus 2006;17:39-47.
  20. Cherqaoui B, Rouel N, Auvrignon A, Defachelles AS, Demeocq F, Kanold J, et al. Peripheral blood stem cell collection in low-weight children: retrospective comparison of two apheresis devices. Transfusion 2014;54: 1371-8. https://doi.org/10.1111/trf.12448